KRAS TCR-Transduced PBL

BIOLOGICAL2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Breast CancerCholangiocarcinomaColorectal CancerDuodenal CancerGastrointestinal CancerGastrointestinal CarcinomaGenitourinary CancerHepatocellular Cancer

Phase 1

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Active, not recruitingNCT06253520

National Cancer Institute (NCI)Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer +4

Start: 2024-05-16End: 2029-02-20Target: 210Updated: 2026-08-14

Phase 2

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

WithdrawnNCT06690281

National Cancer Institute (NCI)Cholangiocarcinoma, Colorectal Cancer, Duodenal Cancer +5

Start: 2025-09-09End: 2025-09-09Updated: 2025-09-11